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ABSTRACT
5′-Vinylphosphonate modification of siRNAs pro-
tects them from phosphatases, and improves silenc-
ing activity. Here, we show that 5′-vinylphosphonate
confers novel properties to siRNAs. Specifically,
5′-vinylphosphonate (i) increases siRNA accumula-
tion in tissues, (ii) extends duration of silencing
in multiple organs and (iii) protects siRNAs from
5′-to-3′ exonucleases. Delivery of conjugated siR-
NAs requires extensive chemical modifications to
achieve stability in vivo. Because chemically modi-
fied siRNAs are poor substrates for phosphorylation
by kinases, and 5′-phosphate is required for load-
ing into RNA-induced silencing complex, the syn-
thetic addition of a 5′-phosphate on a fully modi-
fied siRNA guide strand is expected to be benefi-
cial. Here, we show that synthetic phosphorylation
of fully modified cholesterol-conjugated siRNAs in-
creases their potency and efficacy in vitro, but when
delivered systemically to mice, the 5′-phosphate is
removed within 2 hours. The 5′-phosphate mimic
5′-(E)-vinylphosphonate stabilizes the 5′ end of the
guide strand by protecting it from phosphatases
and 5′-to-3′ exonucleases. The improved stability in-
creases guide strand accumulation and retention in
tissues, which significantly enhances the efficacy
of cholesterol-conjugated siRNAs and the duration
of silencing in vivo. Moreover, we show that 5′-(E)-
vinylphosphonate stabilizes 5′ phosphate, thereby
enabling systemic delivery to and silencing in kid-
ney and heart.
INTRODUCTION
Small interfering RNAs (siRNAs) guide the sequence-
specific cleavage of targeted mRNAs (1,2). The ability to
design and chemically synthesize an siRNA against virtu-
ally any target gene offers a powerful therapeutic strategy
to treat genetic diseases, particularly those for which small
molecule drugs do not exist (such as Huntington′ s dis-
ease and other neurodegenerative diseases). The sequence
of an siRNA determines its target, but the chemical archi-
tecture determines its pharmacokinetic behavior (3). Thus,
siRNAs can readily be tailored to fit the needs of personal-
ized medicine.
The clinical utility of siRNA therapeutics has been lim-
ited by in vivo stability and safe, efficient delivery to tis-
sues. Both challenges are being met by advances in oligonu-
cleotide chemistry (4–7). Hydrophobic conjugates––e.g.
cholesterol––drive efficient cellular uptake of siRNA via a
general mechanism (4,8), which may enable targeting of a
wide range of tissues. Extensive chemical modification of
conjugated siRNAs improves stability and activity in vivo
(4,9,10). siRNA compounds currently in clinical studies are
modified using a combination of 2′-fluoro (2′-F) and 2′-O-
methyl (2′-O-Me) modifications (5,9,11).
The guide strand of an siRNA duplex must bear a 5′-
phosphate to bind the effector protein of the RNA-induced
silencing complex Argonaute 2 (AGO2) (12–15). The in
vivo phosphorylation state of a synthetic siRNA depends
on the balance of kinase and phosphatase activity. A de-
phosphorylated siRNA must be phosphorylated for effec-
tiveness in vivo; however, fully chemically modified siRNAs
are poor substrates for intracellular kinases (16). Therefore,
to preserve proper 5′ phosphorylation, phosphonates can
be used as metabolically stable phosphate analogs. The sta-
bility resides in the carbon-phosphorus bond of phospho-
nates that resists phosphatases, which hydrolyze oxygen-
phosphorus bonds (17). Among phosphonates tested, 5′-
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(E)-vinylphosphonate appears to be the most effective
phosphate analog in siRNAs (18–21). Indeed, both single
stranded siRNAs andGalNAc-conjugated double stranded
siRNAs benefit from 5′-(E)-vinylphosphonate modification
(22–25).
Here we evaluate how chemical phosphorylation of hy-
drophobically modified siRNAs (hsiRNAs) with either
phosphate, or the metabolically stable phosphate analog 5′-
(E)-vinylphosphonate, impacts efficacy and duration of ef-
fect in vitro and in vivo. We show that 5′-phosphate and
5′-(E)-vinylphosphonate equally enhance hsiRNA activity
in vitro. When administered in vivo, 5′-phosphate hsiR-
NAs are de-phosphorylated within hours, but metabolic
stabilization with 5′-(E)-vinylphosphonate significantly in-
creases retention of hsiRNAs in tissues, silencing activ-
ity, and duration of effect. The 5′-(E)-vinylphosphonate,
cholesterol-conjugated hsiRNAs remain active in liver and
kidneys for at least 6 weeks after single administration.
5′-(E)-vinylphosphonate hsiRNAs silences target genes in
the heart, a tissue previously not accessible by conjugated
siRNAs. Finally, we show that 5′-(E)-vinylphosphonate
not only resists phosphatases in vivo, but also resists 5′-
phosphate-dependent exonucleolytic destruction byXRN1,
contributing to overall stabilization of the guide strand in
tissues.
MATERIALS AND METHODS
mRNA quantification from cells and tissue punches
HeLa cells (ATCC, #CCL-2) were plated in DMEM (Cell-
gro, #10-013CV) supplemented with 6% fetal bovine serum
(FBS; Gibco, #26140) at 10 000 cells per well in 96-well
tissue culture plates. hsiRNA was diluted in OptiMEM
(Gibco, #31985-088) and added to cells, resulting in 3%
FBS. Cells were incubated for 72 h at 37◦C, 5% CO2. Cells
were lysed and mRNA quantification was performed us-
ing the QuantiGene 2.0 assay kit (Affymetrix, #QS0011)
as described previously (26). For in vivo experiments, mice
were euthanized and organs placed in RNAlater (Sigma,
#R0901) at 4◦C overnight. Then tissue punches (∼10 mg)
were taken using 1.5 mm disposable biopsy punch with
plunger (Integra, Miltex, # 33-31A-P/25). Tissue punches
were lysed and mRNA quantification was performed using
the QuantiGene 2.0 assay kit (Affymetrix, #QS0011) as de-
scribed previously (26). Catalog numbers for probes used
in QuantiGene 2.0 assay kit are as follows: human HTT
(Affymetrix, #SA-50339), mouse Htt (Affymetrix, #SB-
14150), human PPIB (Affymetrix, #SA-10003), mouse
Ppib (Affymetrix, #SB-10002), humanHPRT (Affymetrix,
#SA-10030), mouse Hprt (Affymetrix, #SB-15463). Data
sets were normalized to housekeeping gene HPRT.
In both in vitro and in vivo experiments, hsiRNAPPIB was
used as non-targeting control (NTC) forHTT silencing, and
hsiRNAHTT was used as non-targeting control (NTC) for
PPIB silencing.
PNA (peptide nucleic acid) based assay for quantitation of
hsiRNA and detection of hsiRNA metabolites in mouse tis-
sues
Tissues punches (10 mg) were lysed in 100 l MasterPure™
Tissue Lysis Solution (EpiCentre®) in the presence of pro-
teinase K (2 mg/ml; Invitrogen, #25530-049) in TissueL-
yser II (Qiagen). SDS was precipitated from the lysate us-
ing KCl (3M) and pelleted at 5000 × g for 15 min. hsiRNA
in cleared supernatant was annealed to a Cy3-labeled PNA
that was fully complementary to the guide strand (PNABio,
Thousand Oaks, CA, USA) by heating to 95◦C for 15 min,
incubating at 50◦C for 15 min, and cooling to room tem-
perature. Tissue lysates containing PNA-guide strand hy-
brids were injected into HPLC DNAPac® PA100 anion-
exchange column (Thermo Fisher Scientific Inc.), Cy3 flu-
orescence was monitored, and peaks were integrated. The
mobile phase for HPLC was Buffer A (50% water, 50%
acetonitrile, 25 mM Tris–HCl, pH 8.5, 1 mM EDTA) and
Buffer B (800 mMNaClO4 in buffer A). For hsiRNA guide
strand quantitation, a steep gradient of Buffer B (10–100%
in 2.5 min) was used, and for hsiRNA guide strand metabo-
lite detection a shallow gradient of Buffer B (10–100% in 18
min) was applied. For calibration curve, known amounts
of hsiRNA duplex was spiked into the tissue lysis solu-
tion derived from untreated mice before annealing to PNA.
Fluorescent peaks (excitation 550 nm, emission 570 nm)
corresponding to hsiRNA-guide strand–PNA hybrid were
recorded, integrated and calibration curve generated by cor-
relating the area under the curve (AUC) of the hsiRNA-
PNA fluorescent peak with the spiked amounts of hsiRNA
duplex.
Animal experiments
Animal experiments were performed in accordance with
guidelines of University of Massachusetts Medical School
Institutional Animal Care and Use Committee (IACUC,
protocol number A-2411). Mice were 6- to 10-week old at
the time of experiments. All animals were kept on a 12-h
light/dark cycle in a pathogen-free facility, with food and
water provided ad libitum.
For systemic administration of hsiRNA, FVBNj female
mice were injected with either phosphate buffered saline
(PBS) or with different amounts of hsiRNA resuspended in
PBS, either through the tail vein or subcutaneously at the
nape of the neck.
After a time of incubation––indicated on individual
figures––mice were deeply anesthetized with 0.1% Avertin,
and after cervical dislocation, tissues were harvested and
stored in RNAlater (Sigma, #R0901) for later use. We used
a single injection per mouse in each experiment.
Statistical analysis
Data were analyzed using GraphPad Prism 7 soft-
ware. IC50 curves were fitted using log(inhibitor) versus
response––variable slope (four parameters). For in vivo sys-
temic silencing, the significance was calculated using One-
way ANOVA with Bonferroni′ s multiple comparisons. To
compare hsiRNA guide strand concentrations measured by
PNA assay, the data were analyzed by One-Way ANOVA
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with Tukey′ s multiple comparisons. For in vivo duration
of effect, the data were analyzed by two-way ANOVA with
Holm–Sidak correction.Differences were considered signif-
icant atP values<0.05 compared to the PBS injected group.
In vitro XRN1 resistance assay
hsiRNA guide strands (30 pmol) were incubated in water or
with 1 l Terminator™ (EpiCentre) exonuclease overnight
at 37◦C in buffer A (EpiCentre, provided with Terminator™
enzyme). Then Novex® high-density TBE sample buffer
(5×) (Thermo Fisher Scientific) was added to samples and
loaded to polyacrylamide gel. Denaturing polyacrylamide
gels (24%) were made in house using a mixture of 4 ml
10× TBE (Tris/borate/EDTA buffer), 17 g urea, 14 ml
acrylamide:bis-acrylamide (19:1) 40% solution (Bio-Rad),
400 l of 10% APS (ammonium persulfate) and 30 l of
TEMED (tetramethylethylanediamine). Urea–PAGE was
performed in 1×TBE at 500 V at room temperature (SE600
system, Hoefer) for ∼6 h. Gels were stained with SYBR®
GoldNucelicAcidGel Stain (ThermoFisher Scientific) and
imaged with Typhoon FLA 9000 (GE Healthcare).
RESULTS
5′ Chemical phosphorylation enhances hsiRNA efficacy in
vitro
Hydrophobically modified hsiRNAs (Figure 1A) are asym-
metric siRNAs with alternating 2′-F and 2′-O–Me mod-
ification of each ribose to resist endonucleases and to
avoid innate immune activation. The 2′-F and 2′-O–Me
modifications offset each other in the short (15 base-pair)
double-stranded region. Phosphorothioate linkages at the
ends of both strands and throughout the single-stranded
3′ tail of the guide strand enhance cellular uptake of hsiR-
NAs. A cholesterol group linked to the 3′ end of the pas-
senger strand drives unassisted cellular uptake. hsiRNAs
rapidly (within minutes) and efficiently enter cells through
an EEA1-related endocytosis pathway (27), and they show
in vivo efficacy after local administration (4,28,29).
hsiRNAs targeting PPIB (peptidylprolyl isomerare B or
cyclophilin B) andHTT (huntingtin) were synthesized with
5′-hydroxyl and 5′-phosphate on the guide strand (see Sup-
plementary Table S1 for sequences and chemical modifi-
cation patterns of hsiRNAs used in this study). Chemical
phosphorylation at the 5′ end significantly increased the
level of target mRNA silencing and hsiRNA potency (2.7-
fold for hiRNAPPIB, p < 0.001 and 1.6-fold hiRNAHTT, p
= 0.01) compared to 5′-hydroxyl hsiRNA. Thus, chemical
phosphorylation significantly contributes to the overall po-
tency of hsiRNAs in vitro in passive uptake, with the level
of impact showing sequence dependence.
hsiRNAs are quickly dephosphorylated in vivo after systemic
administration
Efficient delivery of conjugated hsiRNA requires chemi-
cal modifications that are resistant against metabolic cleav-
age. To evaluate metabolic stability of chemically intro-
duced 5′-phosphate in vivo, we administered 10 mg/kg of
5′-phosphate hsiRNA systemically into mice by tail vein in-
jection.We analyzed the livers of injected mice after 2, 24 or
120 hours for the presence of hsiRNA guide strandmetabo-
lites. For comparison, we also analyzed a series of predicted
guide strand metabolites (references), which we added into
liver lysates from PBS treated animals (Supplementary Fig-
ure S1A and Supplementary Figure S2). Tissues were lysed
and hsiRNA guide strand metabolites were detected us-
ing a peptide nucleic acid (PNA)-based hybridization as-
say (30) and anion exchange chromatography. Correlation
of elution times between the references and metabolites ex-
tracted from mouse livers identified major hsiRNA degra-
dation products.
We failed to detect intact hsiRNA guide strands in liv-
ers harvested 2 hours after injection (Supplementary Figure
S1B), indicating that systemically administered hsiRNAs,
in spite of being fully modified by 2′-F and 2′-O–Me, are
rapidlymetabolized in vivo. At each time point, we observed
two major chromatography peaks whose elution times cor-
related with that of a 5′-hydroxyl full-length (20-nucleotide)
guide strand and a 5′-hydroxyl 19-nucleotide metabolite
with one nucleotide removed from the 3′ end (Supplemen-
tary Figure S1B).Mass spectrometry analysis confirmed the
identity of both metabolites (Supplementary Figure S1C),
and resolved additional products, including a 5′-phosphate
metabolite trimmed at the 3′ end by 1 nucleotide (product 2,
Supplementary Figure S1A) and further 5′-hydroxyl prod-
ucts trimmed at the 3′ end by two or three nucleotides (prod-
ucts 4 and 5 in Supplementary Figure S1A). At 2 hours af-
ter injection, most of the hsiRNA guide strand was dephos-
phorylated at the 5′ end, and by 24 hours the levels of full-
length 5′-phosphate guide strand could not be distinguished
from noise. Thus, the primary degradation events in vivo ap-
pear to be eliminating of the 5′-phosphate and trimming the
3′ end. Although RISC should be able to load a phospho-
rylated guide strand trimmed by one or two 3′ nucleotides
(31), dephosphorylated guide strands are expected to be sig-
nificantly less active, thereby limiting in vivo efficacy.
5′-(E)-Vinylphosphonate modification could be added to all
sequences of hsiRNA and is fully active in vitro
We sought to compare the stability and activity of hsiR-
NAs with 5′-phosphate or a metabolically stabilized 5′-
(E)–vinylphosphonate. The unsaturated C–C bond of 5′-
(E)–vinylphosphonate restricts the torsion angle to 180◦,
and the resulting trans- or E-configuration mimics the op-
timal electronic and spatial positioning of 5′-phosphate
(20) (Figure 2A). We synthesized the phosphoramidite
of 5′-(E)-vinylphosphonate 2′-O–Me-uridine and incorpo-
rated it into the guide strand as a last coupling during
the 3′-5′ oligonucleotide chemical synthesis. Since 5′ ter-
minal base is not involved in RISC - target mRNA in-
teraction (25,32), the 5′-(E)-vinylphosphonate 2′-O–Me-
uridine phosphoramidite can be used to incorporate 5′-
(E)-vinylphosphonate in any siRNA independently of
target gene and sequence (Figure 2 and Supplemen-
tary Figure S3). When tested in vitro by passive up-
take, 5′-(E)-vinylphosphonate hsiRNAs were just as ef-
fective as 5′-phosphate hsiRNAs, confirming that the 5′-
(E)-vinylphosphonate modification is well tolerated by the
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Figure 1. 5′ phosphorylation of hsiRNAs increases activity in vitro. (A) Cartoon of hsiRNA chemical scaffold. (B) Graphs showing the levels of PPIB (left)
or HTT mRNA (right) in HeLa cells treated with 5′-hydroxyl (5′-OH) or 5′-phosphate (5′-P) hsiRNAPPIB (left) or hsiRNAHTT (right) or non-targeting
control (NTC) hsiRNAs. mRNA levels measured by QuantiGene® 2.0 assay are normalized to the level of a controlHPRTmRNA and shown as percent
of the untreated (UNT) control. The IC50 for the experimental hsiRNAs are indicated in the legend. N = 3 for each datapoint.
RNA-induced silencing complex (RISC) assembly (Figure
2B).
5′-(E)-Vinylphosphonate hsiRNA outperforms 5′-phosphate
hsiRNA in kidney and heart, and is comparable in liver and
spleen
Current clinical stage siRNAs accumulate in liver (7,10).
Therefore, we first compared the efficacy of 5′-hydroxyl,
5′-phosphate and 5′-(E)-vinylphosphonate hsiRNAs in the
liver after intravenous or subcutaneous administration. We
used previously identified hsiRNA sequences that efficiently
silence Ppib or Htt mRNAs (Supplementary Table S1;
(4,28)). All 5′ variants of hsiRNAHtt reduced Htt mRNA
levels in liver by ∼60% when administered subcutaneously
and by ∼40% when administered intravenously (Figure 3).
In contrast, 5′-(E)-vinylphosphonate modified hsiRNAPpib
silenced Ppib mRNA substantially better (66% when ad-
ministered subcutaneously and 57% when administered in-
travenously) than 5′-phosphate or 5′-hydroxyl hsiRNAs
(30–50% when administered subcutaneously and 25–30%
when administered intravenously)(Figure 3).
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Figure 2. Stabilization of the 5′ end by 5′-(E)-vinylphosphonate supports RISC loading and activity. (A) Chemical structures of 5′phosphate (5′-P) and
5′-(E)-vinylphosphonate (5′-VP). (B) Except that HeLa cells treated with 5′-P or 5′ -VP modified hsiRNAs, as indicated in the legend.
The cholesterol moiety conjugated to hsiRNAs is highly
hydrophobic and drives non-specific uptake of hsiRNA by
many cell and tissue types such asmuscle (8) and eye (4).We
therefore asked whether subcutaneous delivery of hsiRNA
could promote silencing in other organs. We specifically
looked at kidney as this is prime location for drug clear-
ance, spleen as a major member of the reticuloendothe-
lial system, and heart as a clinically interesting target or-
gan. Since hsiRNA accumulation was expected to be sub-
stantially lower in these organs (i.e. kidneys, heart and
spleen) than in liver, we used a higher dose (20 mg/kg) to
ensure sufficient hsiRNA accumulation in secondary tis-
sues to support silencing. Subcutaneous administration of
5′phosphate hsiRNAPPIB silenced Ppib mRNA by 28% in
spleen (Supplementary Figure S4) but did not lead to si-
lencing in kidney and heart. 5′-phosphate hsiRNAHTT did
not result in silencing Htt mRNAs in kidney, spleen or
heart (Figure 3). The 5′-hydroxyl hsiRNAs supported 50%
silencing of Ppib and 20% silencing of Htt in kidney, 15%
Ppib silencing but no Htt silenicing in spleen (Supplemen-
tary Figure S4) and no Ppib silencing but 35% Htt silenc-
ing in heart (Figure 3). The metabolically stabilized 5′-(E)-
vinylphosphonate hsiRNAs showed the highest activity,
showing 64% Ppib mRNA silencing and 40% Htt mRNA
silencing in kidney (Figure 3), 32% Ppib silencing and 25%
Htt silencing (P = 0.06) in spleen (Supplementary Figure
S4), as well as 46% Ppib silencing and 51% Htt silencing in
heart (Figure 3).
5′-(E)-Vinylphosphonate improves hsiRNA accumulation in
multiple tissues
Using the PNA-based hybridization assay to quantify
hsiRNA levels in tissue lysates, we found that the metaboli-
cally stable 5′-(E)-vinylphosphonate hsiRNAs accumulated
to significantly higher concentrations (up to 22-fold) than
5′-hydroxyl hsiRNAs in liver, kidney, heart, and spleen (Fig-
ure 4A and B). When administered intravenously, the pos-
itive impact of 5′-(E)-vinylphosphonate modification on
hsiRNA concentration was the highest in heart (Figure
4B). In all tissues examined, 5′-(E)-vinylphosphonate hsiR-
NAs accumulated to higher levels than 5′-phosphate hsiR-
NAs, regardless of the administration route or hsiRNA se-
quence (Figure 4A and B). Hence, the metabolic stabiliza-
tion of the 5′-phosphate via 5′-(E)-vinylphosphonate has re-
sulted in overall increase of guide strand tissue accumula-
tion, which could explain improved in vivo activity of 5′-(E)-
vinylphosphonate hsiRNAs.
5′-(E)-vinylphosphonate modification of hsiRNA confers re-
sistance to phosphatases and to 5′-to-3′ exoribonuclease
XRN1
The improved retention and silencing activity of 5′-(E)-
vinylphosphonate hsiRNAs in vivo could reflect protection
from natural phosphatases and nucleases.
Phosphonate bonds have been shown to resist snake
venom phosphatase (17,20) and 5′-(E)-vinylphosphonate
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Figure 3. 5′ -(E)-vinylphosphonate modification enhances hsiRNA efficacy in liver, kidneys and heart column scatter plots showing Ppib or Htt mRNA
levels in the livers, kidneys and hearts of mice (n = 5 per group) treated with 5′-hydroxyl (5′-OH), 5′-phosphate (5′-P), or and 5′-(E)-vinylphosphonate
(5′-VP) hsiRNAs by intravenous (IV) of subcutaneous (SC) injection. mRNA levels measured by QuantiGene® 2.0 assay, were normalized toHprtmRNA
and expressed as percent of mRNA levels in PBS-treated animals. NTC, non-targeting control. T, targeting hsiRNA. Significance calculated by ANOVA
with Bonferroni′ s correction: ns, non-significant; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 and ****P ≤ 0.0001.
siRNAs have performed better in vivo than 5′-hydroxyl siR-
NAs (Figure 3, (23,24)) consistent with phosphatase re-
sistance. However, no direct evidence exists to date that
5′-(E)-vinylphosphonate resist phosphatases in vivo in a
mouse. We therefore used a PNA-based hybridization
assay (30) to resolve phosphorylated and dephosphory-
lated hsiRNA metabolites in liver lysates from mice in-
jected with 20 mg/kg 5′-hydroxyl, 5′-phosphate or 5′-(E)-
vinylphosphonate hsiRNAs. As a control, we analyzed un-
treated liver lysates, into which we added intact hsiRNAs
with 5′-hydroxyl, 5′-phosphate, or 5′-(E)-vinylphosphonate
end. The control chromatography shows 5′-phosphate and
5′-(E)-vinylphosphonate hsiRNAs elute with overlapping
profiles, and 5′-hydroxyl hsiRNAs elute earlier, reflecting
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Figure 4. Metabolic stabilization of the 5′ phosphate increases retention in both primary and secondary tissues. (A) Bar graphs showing the concentra-
tions of 5′-hydroxyl (5′-OH), 5′-phosphate (5′-P), or and 5′-(E)-vinylphosphonate (5′-VP) hsiRNA guide strands and their metabolites in liver (primary
tissue), kidneys, heart and spleen (secondary tissues), one week after intravenous (IV) or subcutaneous (SC) injection. Concentrations measured by PNA
hybridization assay. Bar graphs show the mean± SD, n= 5 mice per group. (B) Summary of fold change in concentrations of 5′-P and 5′-VP hsiRNA guide
strands compared to 5′-OH hsiRNA guide strand. Fold changes are color-coded: high fold changes in red and low fold changes in white. Fold changed
were calculated by dividing average hsiRNA concentrations in respective organs from n = 5 mice per group.
the difference of one charge (the phosphate) absent in the
5′-hydroxyl hsiRNA (Figure 5A, left panels). In livers har-
vested from mice 1 week after injection, however, we found
that chromatography profiles of 5′-phosphate hsiRNA con-
verged with the profile of 5′-hydroxyl hsiRNA, whereas
5′-(E)-vinylphosphonate hsiRNA guide strand eluted later
(Figure 5A, middle and left graphs), regardless of adminis-
tration route or sequence. These findings are consistent with
rapid dephosphorylation (and 3′ trimming) of 5′-phosphate
hsiRNA and protection of 5′-(E)-vinylphosphonate hsiR-
NAs from dephosphorylation.
Nucleic acids with a 5′ phosphate are sensitive to the
5′-to-3′ exoribonuclease XRN1 (33). Furthermore, XRN1
and XRN2 play a role in miRNA stability (34–36), es-
pecially if miRNA is taken up from the extracellular
space (37). XRN1 also regulates accumulation of viral
dsRNA (38). Taken together with the observation that
5′-(E)-vinylphosphonate hsiRNA showed higher concen-
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Figure 5. 5′ -(E)-vinylphosphonate infers resistance against phosphatases in vivo and 5′-3′ exonuclease in vitro. (A) HPLC traces of Cy3-PNA/hsiRNA
hybrids in liver lysates from mice harvested 1 week after intravenous (IV) or subcutaneous (SC) injection with 5′-hydroxyl (5′-OH), 5′-phosphate (5′-P), or
and 5′-(E)-vinylphosphonate (5′-VP) hsiRNA. The ‘spike-in’ (left) panels show control traces of Cy3-PNA/hsiRNA hybrids after full-length guide strands
were spiked into liver lysates from untreatedmice. 5′-P spike-in guide strands elute more slowly than 5′-OH guide strands, corresponding to the difference of
one charge (phosphate). Metabolite profile in liver lysates clearly show dephosphorylation of 5′-P hsiRNA but partially intact 5′ end of 5′-VP hsiRNA. (B)
Urea-PAGE of 5′-hydroxyl (5′-OH), 5′-phosphate (5′-P), or and 5′-(E)-vinylphosphonate (5′-VP) hsiRNAs resolved on an 7 M urea/24% polyacrylamide
gel after 12 h incubation in the absence (–) or presence (+) of Terminator™ enzyme. 5′-P and 5′-VP (no PS) compound had the same nucleotide modification
pattern (2′-F, 2′-O-Me) as 5′-P, 5′-OH and 5′ -VP, but did not contain phosphorothioate (PS) internucleotide linkages. 5′-VP hsiRNA is protecting against
degradation by Terminator™ enzyme, whereas 5′-P hsiRNA is degraded, and phosphorothioate internucleotide linkage interferes with enzyme processivity.
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trations in several tissues than 5′-phosphate hsiRNA,
we hypothesized that 5′-(E)-vinylphosphonate hsiRNA
may have improved stability due to XRN1 resistance.
To test whether 5′-(E)-vinylphosphonate modification pro-
tects against 5′-to-3′ exoribonuclease-mediated degrada-
tion, we treated 5′-phosphate, 5′-hydroxyl, and 5′-(E)-
vinylphosphonate hsiRNA guide strands with Terminator™
5′-phosphate-dependent exoribonuclease (i.e. recombinant
XRN1) overnight and then resolved potential metabo-
lites by denaturing polyacrylamide gel electrophoresis.
Whereas we detected a 5′-phosphate hsiRNA guide strand
metabolite shortened by ∼1 nt, the 5′-hydroxyl and 5′-
(E)-vinylphosphonate hsiRNA guide strands––regardless
of sequence––remained intact (Figure 5B). This find-
ing indicates that 5′-(E)-vinylphosphonate protects against
turnover by 5′-phosphate-specific exoribonucleases. We hy-
pothesized that the 19mer metabolite of 5′-phosphate
hsiRNA could be a result of interference between phos-
phorothioate internucleotide linkage with XRN1 proces-
sivity. Therefore, we synthesized 5′-phosphate and 5′-
(E)-vinylphosphonate hsiRNAs fully modified with 2′-O-
Me and 2′-F but containing no phosphorothioates. The
guide strand of 5′phosphate hsiRNA lacking phospho-
rothioates was fully degraded by Terminator™, whereas
5′-(E)-vinylphosphonate hsiRNA guide strand containing
no phosphorothioates was protected (Figure 5B). These
data suggest that 5′-(E)-vinylphosphonate modification is
sufficient to protect hsiRNA guide strand from degra-
dation by 5′-to-3′ exoribonuclease. Overall, resistance to
phosphatases and to the exoribonuclease XRN1 underlie
the improved in vivo stability of 5′-(E)-vinylphosphonate -
modified hsiRNAs, leading to improved silencing perfor-
mance.
5′-(E)-vinylphosphonate modification improves hsiRNA du-
ration of effect in vivo
The improved in vivo stability and silencing performance of
5′-(E)-vinylphosphonate hsiRNA could translate into im-
proved duration of effect. We tested this hypothesis by sub-
cutaneously injecting a single 20 mg/kg dose of 5′-hydroxyl
or 5′-(E)-vinylphosphonate hsiRNAPpib andmonitoring the
levels of Ppib mRNA and hsiRNA in mouse kidney and
liver at different time points. We found that the silencing of
Ppib mRNA and hsiRNAPpib concentration in kidney and
liver gradually decreased with time, but the level of Ppib
mRNA silencing and retention of 5′-(E)-vinylphosphonate
hsiRNA exceeded that of 5′-hydroxyl hsiRNA at each time
point (Figure 6).Metabolically stable phosphate containing
5′-(E)-vinylphosphonate hsiRNAmaintained significant si-
lencing in liver and kidney, from ∼70% Ppib mRNA si-
lencing in both tissues after 1 week to ∼24% (liver) and
∼17% (kidney) silencing after 6 weeks. The 5′-hydroxyl
hsiRNA showed∼50% target mRNA silencing after 1 week
in both liver and kidney, but lost significant silencing ac-
tivity within 4 weeks in liver and within 2 weeks in kidney
(Figure 6A). The 5′-(E)-vinylphosphonate hsiRNA concen-
tration remained two to four times higher than the concen-
tration of 5′-hydroxyl hsiRNA in liver and kidney at each
time point (Figure 6B). Hence, stabilization of 5′ end by 5′-
(E)-vinylphosphonate supports increased tissue content, in-
creased silencing activity and increased duration of effect
when compared to 5′hydroxyl hsiRNA.
DISCUSSION
Here, we have shown that 5′-(E)-vinylphosphonate mod-
ification confers clinically useful properties to siRNA
drugs. These properties include increase in siRNA tis-
sue concentration and duration of silencing, which in
turn may allow lowering of dose and frequency of ad-
ministration. We have identified two underlying mecha-
nisms: resistance to phosphatases and resistance to 5′-to-
3′ exonucleases. We and others have shown that 5′-(E)-
vinylphosphonate is recognized as a phosphate mimic by
AGO2 (a nuclease in the RNA-induced silencing complex,
RISC) and allows or even facilitates loading of siRNA
guide strand into RISC (23,25). However, our data suggests
that 5′-(E)-vinylphosphonate is not recognized as a phos-
phate mimic by the main cytoplasmic 5′-to-3′ exonuclease,
XRN1. Hence, 5′-(E)-vinylphosphonate modification im-
proves both the pharmacodynamic (better loading toRISC)
and pharmacokinetic (slower degradation) behavior of an
siRNA through altering protein binding.
The impact of 5′-(E)-vinylphosphonate on siRNA silenc-
ing activity showed sequence-dependence in liver but not
in kidney and heart. Different hsiRNA-to-target mRNA
ratios could explain this observation. In mouse liver, Ppib
mRNA is expressed at a fifty times higher level than Htt
mRNA (FPKM ∼184 versus FPKM ∼4; Proteinatlas.org),
whereas hsiRNAPPIB and hsiRNAHTT concentrations were
very similar (∼200 ng/mg). Therefore, the injected dose
of 5′-phosphate or 5′-hydroxyl hsiRNA may be above the
level needed to fully silence Htt in liver, but below the level
needed to fully silence Ppib. Increased concentration of 5′-
(E)-vinylphosphonate hsiRNA would therefore improve si-
lencing of Ppib but not that ofHtt. hsiRNA concentrations
are approximately six times lower in kidney and twenty
times lower in heart than in liver, while mRNA expres-
sion levels are within the same range. We propose that 5′-
(E)-vinylphosphonate only improves silencing activity when
hsiRNA-to-target mRNA ratios are below the level of sat-
uration.
We observed that modification of the 5′ end of hsiR-
NAs influenced silencing activity differently in vitro and in
vivo. First, 5′-(E)-vinylphosphonate hsiRNA was equally
active in vitro compared to 5′-phosphate hsiRNA, but sig-
nificantly more active in vivo. This is explained by rapid
dephosphorylation of 5′-phosphate hsiRNA in vivo (Sup-
plementary Figure S1 and (39)) In parallel, 5′-hydroxyl
hsiRNA was less active in vitro but more active in vivo
compared to 5′-phosphate hsiRNA. Indeed, unmodified 5′-
hydroxyl siRNA has been found to be more efficacious in
vivo than unmodified 5′-phosphate siRNA (40). Further-
more, all siRNAs showing efficacy to date in clinical trials
have 5′-hydroxyl ends (11,41,42). The mechanism why 5′-
hydroxyl siRNA performs superior to 5′-phosphate siRNA
in vivo is unclear. We propose that the 5′ end of the guide
strand may influence protein binding profile of the siRNAs
in subcutaneous extracellular space or in serumor in lymph.
siRNA-bound proteins or peptides can alter the trafficking
(43) and phosphorylation (39) of siRNAs. The different im-
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Figure 6. Stabilization of 5′ phosphate increases duration of effect and corresponding tissue accumulation of hsiRNA in vivo. (A) Column scatter plots
showing PpibmRNA levels in the livers and kidneys of mice (n= 5 per group) at the indicated times after subcutaneous injection of PBS or 5′-OH or 5′-VP
hsiRNAs. mRNA levels measured by QuantiGene® assay were normalized to Hprt mRNA and expressed as a percent of mRNA levels in PBS-treated
animals. Significance calculated by ANOVA with Bonferroni′ s correction, significance was calculated in comparison to PBS-treated animals: *P ≤ 0.05;
**P ≤ 0.01; ***P ≤ 0.001 and ****P ≤ 0.0001. Mean ± SD. (B) Bar graphs showing the concentration of 5′-OH and 5′-VP hsiRNA guide strands in liver
and kidney, as measured by the PNA-based hybridization assay at the indicated time points after subcutaneous injection. Mean ± SD, N = 5
pact of 5′end of the guide strand on silencing activity in in
vitro and in vivo experimental settings may be explained by
exposure to a different protein environment.
Concentration of 5′-(E)-vinylphosphonate hsiRNA
was 4–22-fold higher than concentration of 5′-hydroxyl
hsiRNA, while silencing of 5′-(E)-vinylphosphonate
hsiRNA was only 0.9–3.3-fold higher than silencing of
5′-hydroxyl hsiRNA. This phenomenon has been observed
before (23) and indicates a non-linear relationship between
tissue concentration and silencing activity. Resistance to
exonucleases shown in this paper is only one contribu-
tor to the concentration––silencing activity relationship.
Other factors may be proteins or peptides differentially
binding to the different 5′ends of hsiRNAs and influence
phosphorylation (39) or endosomal release (44).
We found better silencing activity following subcuta-
neous administration compared to intravenous administra-
tion, as has been observed in the case ofGalNac-conjugated
siRNAs as well (7). Subcutaneous administration results
in slower release and longer residence time of the hsiRNA
compared to intravenous administration. We speculate that
certain serum proteins carry hsiRNAs to the organs and the
hsiRNA binding capacity of the serum is saturated upon
intravenous administration. Binding to the proper carrier
protein may enable a productive cellular entry pathway.
In this study, we used hsiRNA modified with a com-
bination of 2′-F, 2′-O-Me and phosphorothioates. These
siRNA modifications can support a duration of silencing
up to 6 months in vivo (11). The mechanism may be ex-
plained by enhanced nuclease stability and formation of
an intracellular depot, which is slowly releasing siRNAs
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for continuous reloading of AGO2 (45). However, recent
findings suggest that reduction of 2′-F modification of an
siRNA could improve safety profiles (11,46,47). Thus, care-
fully fine-tuning the amount of 2′-F modifications in 5′-(E)-
vinylphosphonate hsiRNA might be crucial to ensure clin-
ical safety and success.
5′-(E)-Vinylphosphonate hsiRNA leads to long-lasting
Huntingtin mRNA silencing in liver, heart and kidneys.
Lowering Huntingtin mRNA could be beneficial in treat-
ing peripheral symptoms and improving quality of life of
patients with Huntington’s disease (48–50).
DEFINITIONS
Conjugated siRNA: sense strand of siRNA is covalently
conjugated to a small molecule (i.e. cholesterol), Fully mod-
ified siRNA: all nucleotides are modified at the 2′ posi-
tion with either 2′-F or 2′-O-methyl, Metabolically stabi-
lized phosphate: 5′-(E)-vinylphosphonate.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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